Decision Diagnostics Corp. (DECN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Decision Diagnostics Corp. (DECN) with AI Score 48/100 (Weak). Decision Diagnostics Corp. focuses on developing and distributing diagnostic products and electronic medical record (EMR) technologies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Decision Diagnostics Corp. (DECN) Healthcare & Pipeline Overview
Decision Diagnostics Corp., operating in the medical pharmaceutical sector, develops and distributes diagnostic products, including glucose test strips and EMR technologies. Their focus on at-home testing and cell phone-centric e-health solutions positions them in a niche market, though they face challenges typical of OTC-listed companies with limited resources.
Investment Thesis
Decision Diagnostics Corp. presents a speculative investment opportunity within the healthcare diagnostics market. The company's focus on glucose testing and EMR technologies caters to the growing demand for at-home diagnostics and digital health solutions. However, its OTC listing and limited financial resources pose significant risks. Key value drivers include potential revenue growth from its GenUltimate! line of glucose test strips and the adoption of its EMR technologies. The company's success hinges on securing regulatory approvals, expanding its distribution network, and managing its operating expenses. Investors should carefully consider the risks associated with investing in an OTC-listed company with a small market capitalization and negative profit margins. The company's beta of -0.04 indicates a low correlation with the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 25.2% indicates potential profitability in its product sales, but needs to be scaled.
- Negative Profit Margin of -1499.1% reflects significant operational challenges and the need for improved cost management.
- The company's focus on at-home glucose testing aligns with the growing trend of remote patient monitoring.
- The development of cell phone-centric e-health products positions the company to capitalize on the increasing adoption of mobile health technologies.
- The company's intellectual property portfolio, including patents and trademarks, provides a potential competitive advantage.
Competitors & Peers
Strengths
- Proprietary GenUltimate! glucose test strip technology.
- Focus on niche markets, such as glucose testing for animals.
- Development of cell phone-centric e-health products.
- Intellectual property portfolio.
Weaknesses
- OTC listing and limited access to capital.
- Negative profit margins and financial instability.
- Small market capitalization and limited trading volume.
- Dependence on a limited number of products and services.
Catalysts
- Upcoming: Potential FDA approvals for new diagnostic products.
- Ongoing: Expansion of distribution network through strategic partnerships.
- Ongoing: Development and launch of new EMR technologies.
- Ongoing: Increasing adoption of at-home glucose testing solutions.
- Ongoing: Growth in the global diabetes market.
Risks
- Potential: Competition from larger, more established companies.
- Potential: Regulatory hurdles and the need for FDA approvals.
- Ongoing: Limited financial resources and negative profit margins.
- Ongoing: OTC listing and lack of regulatory oversight.
- Potential: Technological obsolescence and the emergence of new diagnostic technologies.
Growth Opportunities
- Expansion of GenUltimate! Product Line: The company can expand its GenUltimate! line of glucose test strips by introducing new products and features, such as continuous glucose monitoring (CGM) systems and integrated mobile apps. The global CGM market is projected to reach $10 billion by 2027, presenting a significant opportunity for Decision Diagnostics to capture market share.
- Strategic Partnerships: Forming strategic partnerships with healthcare providers, pharmacies, and diabetes management programs can expand the company's distribution network and reach a wider customer base. Collaborating with telehealth companies can also integrate the company's EMR technologies into virtual care platforms, increasing adoption and revenue streams.
- Geographic Expansion: Expanding into new geographic markets, particularly emerging economies with growing diabetes populations, can drive revenue growth. The company can target countries with limited access to healthcare services and a high prevalence of diabetes, offering affordable and accessible glucose testing solutions.
- Development of New EMR Technologies: Investing in the development of new EMR technologies, such as AI-powered diagnostic tools and remote patient monitoring systems, can enhance the company's product portfolio and attract new customers. The global EMR market is projected to reach $40 billion by 2028, indicating a significant growth opportunity for Decision Diagnostics.
- Acquisition of Complementary Businesses: Acquiring complementary businesses in the healthcare diagnostics or EMR space can expand the company's product offerings, customer base, and market share. The company can target companies with innovative technologies or established distribution networks, creating synergies and driving revenue growth.
Opportunities
- Expansion of GenUltimate! product line.
- Strategic partnerships with healthcare providers and telehealth companies.
- Geographic expansion into emerging markets.
- Development of new EMR technologies.
Threats
- Competition from larger, more established companies.
- Regulatory hurdles and the need for FDA approvals.
- Technological obsolescence and the emergence of new diagnostic technologies.
- Economic downturns and reduced healthcare spending.
Competitive Advantages
- Proprietary GenUltimate! glucose test strip technology.
- Intellectual property portfolio, including patents and trademarks.
- Established relationships with healthcare providers and distributors.
- Focus on niche markets, such as glucose testing for animals.
About DECN
Founded in 2000 and based in Westlake Village, California, Decision Diagnostics Corp. (formerly InstaCare Corp.) is a developer, manufacturer, and distributor of diagnostic products and electronic medical record (EMR) technologies. The company's core business revolves around providing solutions for diabetes management, including its GenUltimate! line of glucose test strips designed for at-home use. These strips are Class II medical devices intended for self-monitoring of blood glucose levels. Additionally, Decision Diagnostics offers PetSure! glucose test strips for monitoring glucose in dogs and cats, compatible with legacy glucometers like the Zoetis AlphaTrak. Beyond glucose testing, Decision Diagnostics provides the GenUltimate! 4Pets Glucose system, a proprietary system for testing glucose levels in dogs, cats, and horses. The company also develops and licenses EMR technologies, including MD@Hand, an inpatient/outpatient management suite, Practice Probe, a data mining utility for physician practice management systems, and ResidenceWare, a residential management system. Decision Diagnostics also engages in acquiring and holding intellectual property, including patents, trademarks, and specialty manufacturing equipment, to support its product lines and technology offerings. The company distributes its products and services through a combination of direct sales, partnerships, and distribution agreements.
What They Do
- Develops and manufactures glucose test strips for human and animal use.
- Provides at-home testing products for individuals with chronic illnesses.
- Offers fulfillment services for direct-to-patient diabetes programs.
- Develops cell phone-centric e-health products and technologies.
- Offers EMR technologies for physicians at the point of care.
- Acquires and holds intellectual property, including patents and trademarks.
Business Model
- Sales of GenUltimate! glucose test strips and related products.
- Licensing of EMR technologies to healthcare providers.
- Fulfillment services for diabetes management programs.
- Acquisition and monetization of intellectual property.
Industry Context
The medical diagnostics industry is experiencing growth driven by increasing prevalence of chronic diseases like diabetes, advancements in technology, and a growing demand for point-of-care and at-home testing solutions. The market is competitive, with established players like Abbott and Roche dominating the space. Decision Diagnostics operates in a niche segment, focusing on glucose testing and EMR technologies. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively compete with larger, more established companies. The global medical device market is projected to reach $600 billion by 2025, highlighting the potential for growth in this sector.
Key Customers
- Individuals with diabetes who require at-home glucose monitoring.
- Veterinarians and pet owners who need to monitor glucose levels in animals.
- Physicians and healthcare providers who use EMR technologies.
- Diabetes management programs and telehealth companies.
Financials
Chart & Info
Decision Diagnostics Corp. (DECN) stock price: Price data unavailable
Latest News
-
Financial Review: 10x Genomics (NASDAQ:TXG) & Decision Diagnostics (OTCMKTS:DECN)
defenseworld.net · Feb 20, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DECN.
Price Targets
Wall Street price target analysis for DECN.
MoonshotScore
What does this score mean?
The MoonshotScore rates DECN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Keith Berman
CEO
Keith Berman serves as the CEO of Decision Diagnostics Corp. His background includes experience in managing and developing companies within the healthcare and technology sectors. He has been involved in various aspects of corporate strategy, product development, and business development. His leadership aims to drive innovation and growth within the company's diagnostic and EMR technology offerings.
Track Record: Under Keith Berman's leadership, Decision Diagnostics Corp. has focused on expanding its GenUltimate! line of glucose test strips and developing its EMR technologies. Key milestones include securing regulatory approvals for its products and establishing partnerships to expand its distribution network. However, the company continues to face challenges related to profitability and financial stability.
DECN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Decision Diagnostics Corp. may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier often have limited financial resources, minimal trading volume, and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial resources and negative profit margins.
- OTC listing and lack of regulatory oversight.
- Low trading volume and price volatility.
- Uncertainty regarding financial disclosure and transparency.
- Dependence on a limited number of products and services.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's products and services and their competitive positioning.
- Analyze the company's intellectual property portfolio.
- Determine the company's regulatory compliance status.
- Assess the company's liquidity and trading volume.
- Understand the company's business model and revenue streams.
- Development and distribution of FDA-regulated medical devices (glucose test strips).
- Focus on providing solutions for diabetes management.
- Intellectual property portfolio, including patents and trademarks.
- CEO with experience in the healthcare and technology sectors.
- Long operating history since 2000.
DECN Healthcare Stock FAQ
What does Decision Diagnostics Corp. do?
Decision Diagnostics Corp. operates in the healthcare sector, focusing on the development, manufacture, and distribution of diagnostic products and electronic medical record (EMR) technologies. Their primary product is the GenUltimate! line of glucose test strips, designed for at-home use by individuals with diabetes. Additionally, they offer EMR software solutions for healthcare providers, aiming to improve patient care and streamline administrative processes. The company also caters to the veterinary market with glucose testing products for pets.
What do analysts say about DECN stock?
As of March 16, 2026, there is no readily available analyst coverage or consensus on Decision Diagnostics Corp. due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are either not applicable or unreliable due to the company's negative profit margins and limited trading volume. Investors should conduct their own independent research and consider the risks associated with investing in an OTC-listed company.
What are the main risks for DECN?
Decision Diagnostics Corp. faces several significant risks, including its OTC listing, which implies less stringent regulatory oversight and lower liquidity. The company's negative profit margins and limited financial resources raise concerns about its ability to sustain operations and fund future growth. Competition from larger, more established companies in the medical diagnostics and EMR markets poses a threat to its market share. Regulatory hurdles and the need for FDA approvals can delay or prevent the launch of new products.
What are the key factors to evaluate for DECN?
Decision Diagnostics Corp. (DECN) currently holds an AI score of 48/100, indicating low score. Key strength: Proprietary GenUltimate! glucose test strip technology.. Primary risk to monitor: Potential: Competition from larger, more established companies.. This is not financial advice.
How frequently does DECN data refresh on this page?
DECN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DECN's recent stock price performance?
Recent price movement in Decision Diagnostics Corp. (DECN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary GenUltimate! glucose test strip technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DECN overvalued or undervalued right now?
Determining whether Decision Diagnostics Corp. (DECN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DECN?
Before investing in Decision Diagnostics Corp. (DECN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC-listed companies carry higher risks than exchange-listed companies.